Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies-Reference-Cited by-同舟云学术

Non-receptor Tyrosine Kinases Role and Significance in Hematological Malignancies

Published:2019-09-25 Issue: Volume: Page:
ISSN:
Container-title:Tyrosine Kinases as Druggable Targets in Cancer
language:
Short-container-title:

Author:

Azevedo Ana,Silva Susana,Rueff José

Publisher

IntechOpen

Link

http://www.intechopen.com/download/pdf/66041

Reference174 articles.

1. Lahiry P, Torkamani A, Schork NJ, Hegele RA. Kinase mutations in human disease: Interpreting genotype-phenotype relationships. Nature Reviews. Genetics. 2010;11:60-74

2. Paul MK, Mukhopadhyay AK. Tyrosine kinase—Role and significance in cancer. International Journal of Medical Sciences. 2004;1:101-115

3. Siveen KS, Prabhu KS, Achkar IW, Kuttikrishnan S, Shyam S, Khan AQ , et al. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Molecular Cancer. 2018;17:31

4. Kosior K, Lewandowska-Grygiel M, Giannopoulos K. Tyrosine kinase inhibitors in hematological malignancies. Postȩpy Higieny i Medycyny Doświadczalnej (Online). 2011;65:819-828

5. Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Molecular Cancer. 2018;17:58

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants;iScience;2023-04

2. Hypoxia as a Modulator of Inflammation and Immune Response in Cancer;Cancers;2022-05-04

3. Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses;2022-01-20

4. Recent advances in pharmacological diversification of Src family kinase inhibitors;Egyptian Journal of Medical Human Genetics;2021-06-01

5. Correlation analysis of target selectivity and side effects of FDA-approved kinase inhibitors;2021-03-19